TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1586733
Drug: Prophylactic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic heparin after allogeneic BMT
Study: 3032827
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre tablets
Study: 29447076
Drug: Pork collagen
Normalized name: Pork Collagen
DrugBank: Pork collagen (DB14100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork collagen peptide (CP) 2.5 g/day
Study: 29447076
Drug: Placebo 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2.5 g/day
Study: 20003398
Drug: Cognitive activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive activity intervention consisting of ten 90-minute sessions delivered twice per week over a period of five weeks.
Study: 17312091
Drug: SS-QOL observable
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-QOL observable scales (e.g., activities)
Study: 15334426
Drug: Lumiracoxib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 50 mg twice daily
Study: 15334426
Drug: Lumiracoxib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 200 mg twice daily
Study: 2735156
Drug: Waiting-for-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-for-treatment control group
Study: 28211216
Drug: eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone 50 mg
Study: 24063830
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus atorvastatin 10 mg (Period I)
Study: 24063830
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus atorvastatin 20 mg (Period II)
Study: 24063830
Drug: Ezetimibe plus
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe plus atorvastatin 10 mg (Period I) or atorvastatin 20 mg (Period II)
Study: 21442811
Drug: Early acupuncture
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early acupuncture combined with exercise therapy; Xingnao Kaiqiao needling method applied at Shuigou (GV 26), Baihui (GV 20), Neiguan (PC 6) after vital signs stabilized.
Study: 21442811
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine and/or surgery without rehabilitation therapy (control group).
Study: 22293088
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting parenteral oxytetracycline
Study: 22293088
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting parenteral enrofloxacin
Study: 22293088
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of potassium permanganate solution
Study: 22293088
Drug: Parenteral antibacterials
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibacterials (oxytetracycline or enrofloxacin) for chronic footrot
Study: 8521432
Drug: Annual application
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual application of APF gel with prior dental prophylaxis
Study: 8521432
Drug: Biannual application
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual application of APF gel with prior dental prophylaxis
Study: 8521432
Drug: Annual application
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual application of APF gel without prior dental prophylaxis
Study: 8521432
Drug: Biannual application
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual application of APF gel without prior dental prophylaxis
Study: 19723786
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus CBT
Study: 27702799
Drug: Ixazomib 4
Normalized name: ixazomib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 4 mg with dexamethasone 40 mg
Study: 27702799
Drug: Ixazomib 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib 5.5 mg with dexamethasone 40 mg
Study: 27702799
Drug: Overall (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (both doses of ixazomib)
Study: 23801607
Drug: Tailored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapy regimen (amoxicillin, rabeprazole, and clarithromycin or metronidazole based on mutation detection)
Study: 23801607
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (amoxicillin, rabeprazole, and clarithromycin) in APC control group
Study: 23801607
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (amoxicillin, rabeprazole, and metronidazole) in APM control group
Study: 21120255
Drug: Test antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test antioxidant regimen (facial wash, day lotion, night crème, eye serum)
Study: 16920894
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 200 mg telbivudine
Study: 16920894
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 400 mg telbivudine
Study: 16920894
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 800 mg telbivudine
Study: 16920894
Drug: Repeat doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat doses of 600 mg/d telbivudine
Study: 30446002
Drug: Allopurinol dose
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol dose > CrCL-based dose (R+)
Study: 24816725
Drug: MGN1703 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGN1703 60 mg
Study: 22288389
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) combined with fractional laser therapy
Study: 22288389
Drug: Fractional laser
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional laser therapy alone
Study: 20094802
Drug: Fiber with
Normalized name: HyFIBER Liquid Fiber with FOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber with insoluble 84% polyphenols 4 g twice a day (n = 43)
Study: 12937331
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy and technology-based intervention
Study: 12937331
Drug: Structural ecosystems
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural ecosystems therapy
Study: 12937331
Drug: Structural ecosystems
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural ecosystems therapy + computer-telephone integrated system
Study: 10403596
Drug: Licensed influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed influenza vaccine
Study: 10403596
Drug: Subpotent influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subpotent influenza vaccine
Study: 7825615
Drug: Hypoglycemia (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (2.2 mmol/L)
Study: 7825615
Drug: Epinephrine, norepinephrine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine, norepinephrine, cortisol, growth hormone, glucagon levels measured at each glucose plateau
Study: 7825615
Drug: Hyperglycemia (21.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (21.1 mmol/L)
Study: 19148113
Drug: Intervention involving
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention involving parents (e.g., parent education, infant stimulation, home visits, individualized developmental care)
Study: 15547184
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A)
Study: 15547184
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment alone (group B)
Study: 15547184
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) among operable patients
Study: 15547184
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment alone (group B) among operable patients
Study: 15547184
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) among inoperable patients
Study: 15547184
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment alone (group B) among inoperable patients
Study: 11535479
Drug: Droperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (5 mg IM or 2.5 mg IV)
Study: 11535479
Drug: Prochlorperazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (10 mg IM or 10 mg IV)
Study: 9481998
Drug: Indomethacin phonophoresis
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin phonophoresis (1% indomethacin cream with ultrasound massage at 1.0 MHz, 0.8 to 1.5 W/cm2 for 15 minutes)
Study: 9481998
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream with ultrasound massage (1.0 MHz, 0.8 to 1.5 W/cm2 for 15 minutes)
Study: 8174987
Drug: Paroxetine 30
Normalized name: PARoxetine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 30 mg daily for five days
Study: 28737966
Drug: Nasal corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal corticosteroid treatment (mometasone)
Study: 25006066
Drug: High S
Normalized name: HIGH SELENIUM YEAST
Approvals — FDA: no, EMA: no, PMDA: no
Description: High S diet + 300 mg of ferric Fe from FAC/kg DM (HS+Fe)
Study: 11095440
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Humatrope, Eli Lilly & Co.) at a dose of 0.05 IU/kg/week for 1 month, then 0.1 IU/kg/week divided into daily subcutaneous injections (0.75-1.25 IU/day) for 6 months followed by 12 months of open treatment.
Study: 11095440
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 6 months.
Study: 4045047
Drug: No digitalis
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: No digitalis therapy (placebo)
Study: 4045047
Drug: Digitalis therapy
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis therapy (adjusted)
Study: 4045047
Drug: Digitalis therapy
Normalized name: Digitalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitalis therapy (multiple logistic regression)
Study: 3040835
Drug: Prednisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (50 mg/day for 4 days)
Study: 31865633
Drug: U-500R via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-500R via continuous subcutaneous insulin infusion (CSII)
Study: 31865633
Drug: U-500R via
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-500R via multiple daily injections (MDI)
Study: 26168982
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² i.v. on day 1 of 3-week cycle
Study: 26168982
Drug: Nab-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 150 mg/m² i.v. on days 1 and 8 of 3-week cycle
Study: 16848802
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg three times daily (t.i.d.)
Study: 16848802
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily (b.i.d.)
Study: 16848802
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg three times daily (t.i.d.)
Study: 31812337
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for ≤24 hours
Study: 31812337
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for ≥96 hours
Study: 22570108
Drug: Peer and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer and practice team intervention (three monthly calls from trained peer patients and two practice staff visits)
Study: 16648017
Drug: sips and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: sips and gum chewing (treatment, n = 22)
Study: 10229057
Drug: ABT-418 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-418 (6 mg)
Study: 10229057
Drug: ABT-418 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-418 (12 mg)
Study: 10229057
Drug: ABT-418 (23
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-418 (23 mg)
Study: 8915564
Drug: Pimozide (3.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (3.4 ± 1.6 mg)
Study: 8915564
Drug: Haloperidol (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3.5 ± 2.2 mg/day)
Study: 1901083
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of immune globulin (IVIG) per kilogram of body weight
Study: 30679724
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (exact dosage and duration not specified)
Study: 23919483
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol (1 ml/kg body weight of 94% alcohol, 0.75 g/kg)
Study: 18283207
Drug: CONSORT extension
Normalized name: EXTENSION TUBES
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONSORT extension for nonpharmacologic treatments
Study: 8866563
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg troglitazone daily for 12 weeks
Study: 8866563
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg troglitazone daily for 12 weeks
Study: 8866563
Drug: Troglitazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200 mg and 400 mg)
Study: 6088713
Drug: Radiotherapy 6000
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy 6000 rads/7 weeks plus CCNU 130 mg/M2 every 6 weeks
Study: 6088713
Drug: Radiotherapy 6000
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy 6000 rads/7 weeks plus CCNU 75 mg/M2 day 1 plus procarbazine 100 mg/m2 days 1‐14 every 6 weeks
Study: 31819122
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution (40 ml/kg)
Study: 31819122
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose water (20 ml/kg)
Study: 31819122
Drug: 6% tetrastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% tetrastarch (1000 ml)
Study: 31819122
Drug: 10% pentastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% pentastarch (1000 ml)
Study: 29878269
Drug: Multi-ingredient protein-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient protein-based supplement (30 g whey protein, 2.5 g creatine, 500 IU vitamin D, 400 mg Ca, 1500 mg n-3 polyunsaturated fatty acids) taken 2 times/day for 7 weeks
Study: 29878269
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (22 g maltodextrin)
Study: 10654116
Drug: Behavioral Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Family Management with Standard Dose medication (BFMSD)
Study: 10654116
Drug: Behavioral Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Family Management with Targeted Medication (BFMTM)
Study: 7966893
Drug: Purified split‐virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified split‐virion vaccine (n = 927)
Study: 7966893
Drug: Intramuscular placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular placebo (n = 911)
Study: 29788791
Drug: Standard transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard transdermal nicotine (nicotine replacement therapy)
Study: 29788791
Drug: Extended nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended nicotine replacement therapy + adjunct nicotine agent
Study: 26755405
Drug: Stabilization exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilization exercises plus manual therapy
Study: 24894701
Drug: 3'‐aminomethylnicotine Pseudomonas aeruginosa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3'‐aminomethylnicotine Pseudomonas aeruginosa r‐Exoprotein‐conjugated vaccine (400 μg/ml)
Study: 20160441
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g dentifrice containing 1,100 microg/g fluoride
Study: 20160441
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g dentifrice containing 1,100 microg/g fluoride
Study: 20160441
Drug: Brushing time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing time of 30, 45, 60, 120, and 180 seconds with 1.5 g dentifrice
Study: 19019662
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg bolus, 0.04 mg/kg/hr continuous, adjusted every 2 hours)
Study: 15818694
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg twice weekly) for 1 year
Study: 10516937
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg tacrolimus capsules
Study: 10516937
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tacrolimus capsules
Study: 10516937
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tacrolimus doses administered at 7-day intervals
Study: 2060560
Drug: Dexfenfluramine 30
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 30 mg per day for 4 days
Study: 6834501
Drug: Meatal care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meatal care with poly-antibiotic ointment twice daily
Study: 6834501
Drug: Meatal care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meatal care with poly-antibiotic ointment
Study: 6834501
Drug: Meatal care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meatal care with poly-antibiotic ointment in high-risk female patients
Study: 19435491
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (IT) following screening
Study: 11266417
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg/24 h for 3 days)
Study: 11266417
Drug: Co-amoxiclav (45/11.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (45/11.25 mg/kg/24 h for 10 days)
Study: 9835466
Drug: Subcutaneous buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous buffered lidocaine (SQBL)
Study: 9835466
Drug: Subcutaneous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous normal saline with 0.9% benzyl alcohol (SQNS)
Study: 7001488
Drug: Other cream
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other cream (triamcinolone acetonide, neomycin sulphate, nystatin, gramicidin)
Study: 31557945
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 3 mg/kg/body mass
Study: 25977821
Drug: Aggressive surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive surgical eradication of atypical breast lesions (specific intervention details such as dosage and duration are not available)
Study: 9638988
Drug: All trans
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All trans retinoic acid (ATRA) 45 mg/M2/day for 90 days followed by 90 mg/M2 on alternate days till Day 275, combined with low dose cytosine arabinoside (Ara‐C) 10 mg/m2 subcutaneously twice daily for 21 days for a total of 6 cycles.
Study: 8078983
Drug: Amitriptylinoxide (120-360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptylinoxide (120-360 mg daily for 4 weeks)
Study: 8078983
Drug: Doxepine (120-360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepine (120-360 mg daily for 4 weeks)
Study: 30514196
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (1000 IU) for 2 weeks in addition to daily subcutaneous human recombinant erythropoietin (2500 IU/kg) for 5 days and IM or IV magnesium sulphate 250 mg/kg within half an hour of birth, subsequently 125 mg/kg at 24 and 48 hours of life.
Study: 19101739
Drug: ART with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART with Carisolv (chemomechanical caries removal gel)
Study: 17239474
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) 4mg daily (increased to 8mg for some subjects)
Study: 17239474
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IG) 10 units daily (doses increased until fasting glucose <120mg/dl)